Skip to content
  • Clinical Studies
  • Schedule M
  • Stability Studies
  • Pharma GMP
  • Pharma Tips
  • Pharma Books
  • Pharma Validation
  • Pharma Regulatory

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • SOP – Blog Post
  • Toggle search form

SOP for Reporting Serious Adverse Events (SAEs)

Posted on By

Standard Operating Procedure for SAE Reporting

Purpose

This SOP outlines the procedures for identifying, documenting, and reporting serious adverse events (SAEs) in clinical trials and clinical studies. The goal is to ensure participant safety, data integrity, and regulatory compliance by promptly reporting SAEs and taking appropriate actions.

Scope

This SOP applies to all personnel involved in clinical trials and clinical studies, including principal investigators, clinical research coordinators, data management teams, and study sponsors.

Responsibilities

  • Principal Investigator (PI): Oversees SAE reporting and ensures compliance with regulatory requirements.
  • Clinical Research Coordinators: Identify and document SAEs, and report them according to study protocol and regulations.
  • Data Management Team: Manages SAE data and assists with documentation and reporting.
  • Study Sponsors: Provide resources and support for SAE reporting and management.
See also  SOP for Handling Complaints and Feedback

Procedure

  • Identification of SAEs:
    • Monitor study activities and participant health to identify SAEs as they occur.
    • Collect and review data from participant assessments, medical records, and reports from study staff.
  • Documentation:
    • Document each SAE in detail, including the date, nature, severity, and outcome of the event.
    • Record information about the affected participant, such as demographic data and medical history.
  • Assessment and Follow-Up:
    • Assess the SAE to determine its relationship to the study intervention and its impact on the participant.
    • Conduct follow-up assessments and monitoring to track the participant’s condition and response to any interventions.
  • Reporting:
    • Report SAEs to the appropriate parties (e.g., study sponsor, IRB/IEC, regulatory authorities) as required by regulatory guidelines and the study protocol.
    • Ensure timely reporting of SAEs to maintain compliance with regulatory requirements.
  • Corrective and Preventive Actions:
    • Implement corrective actions as needed to address the SAE and prevent recurrence.
    • Document actions taken and communicate them to relevant stakeholders.
See also  SOP for Site Selection and Initiation

Abbreviations Used

  • SOP: Standard Operating Procedure
  • PI: Principal Investigator
  • SAE: Serious Adverse Event
  • IRB/IEC: Institutional Review Board/Independent Ethics Committee

Documents

  • SAE logs and records
  • Assessment and follow-up reports
  • SAE reporting forms

References

  • Institutional policies for SAE reporting
  • Regulatory guidelines (e.g., FDA, EMA, ICH-GCP)
  • Study protocols and investigator brochures

SOP Version

Version: 1.0

Clinical Studies Tags:Adverse event reporting, Clinical data management, Clinical data validation, Clinical research compliance, Clinical research coordination, Clinical site selection, clinical studies, clinical study, Clinical study protocols, Clinical trial management, Clinical trial monitoring, Clinical trial participants, Clinical trial procedures, Clinical trial SOPs, clinical trials, Conflict of interest management, Data collection methods, Data management SOPs, eCRF validation, Electronic record-keeping guidelines, Electronic systems validation, Ethics committee reporting, Investigator training protocols, Participant data privacy, Participant recruitment strategies, Pharmacovigilance protocols, Quality assurance practices, Regulatory compliance procedures, Risk management procedures, Safety monitoring procedures, Site selection criteria, Study protocol development

Post navigation

Previous Post: SOP for Statistical Analysis and Data Interpretation
Next Post: SOP for Community Engagement and Outreach

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • Analytical Method Development V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Biosimilars V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Elixers V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2025 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version